Sai Life Sciences shares hit a fresh 52-week high on Monday after strong Q2 results and bullish brokerage commentary. Jefferies retained its Buy rating and raised its target price to Rs 2,050, citing healthy CRO and CDMO growth, a strengthening pipeline and improved earnings prospects.
Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%
Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target